Week 2-4 : Side effects should diminish as your body re-adjusts
Semaglutide activates GLP-1 receptors throughout your body, lowering appetite, slowing digestion, and regulating blood sugar
[2] Research by Park et al
Retrieved from Yeung, A
Commenting on the MHRA review, Riccardo De Giorgi, clinical lecturer in the department of psychiatry at University of Oxford, said: It is reassuring that the MHRA conclusions regarding the safety of GLP1-RAs in terms of suicidality and depression match those of other international regulatory agencies, such as the EMA and US Food and Drug Administration
Particularly, Semaglutide induced central c-Fos activation in 10 brain areas, including hindbrain areas that it directly targets, as well as secondary regions without direct GLP-1R interaction, such as the lateral parabrachial nucleus (LPB)